150 related articles for article (PubMed ID: 31340981)
1. Hierarchy of mono- and biallelic
Munawar U; Rasche L; Müller N; Vogt C; Da-Via M; Haertle L; Arampatzi P; Dietrich S; Roth M; Garitano-Trojaola A; Steinhardt MJ; Strifler S; Gallardo M; Martinez-Lopez J; Bargou RC; Heckel T; Einsele H; Stühmer T; Kortüm KM; Barrio S
Blood; 2019 Sep; 134(10):836-840. PubMed ID: 31340981
[No Abstract] [Full Text] [Related]
2. Subclonal
Shah V; Johnson DC; Sherborne AL; Ellis S; Aldridge FM; Howard-Reeves J; Begum F; Price A; Kendall J; Chiecchio L; Savola S; Jenner MW; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Davies FE; Houlston RS; Cook G; Cairns DA; Jackson G; Kaiser MF;
Blood; 2018 Dec; 132(23):2465-2469. PubMed ID: 30373884
[TBL] [Abstract][Full Text] [Related]
3. Prognosis, Biology, and Targeting of
Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
[TBL] [Abstract][Full Text] [Related]
4. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Weinhold N; Ashby C; Rasche L; Chavan SS; Stein C; Stephens OW; Tytarenko R; Bauer MA; Meissner T; Deshpande S; Patel PH; Buzder T; Molnar G; Peterson EA; van Rhee F; Zangari M; Thanendrarajan S; Schinke C; Tian E; Epstein J; Barlogie B; Davies FE; Heuck CJ; Walker BA; Morgan GJ
Blood; 2016 Sep; 128(13):1735-44. PubMed ID: 27516441
[TBL] [Abstract][Full Text] [Related]
5. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
[TBL] [Abstract][Full Text] [Related]
6. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
[TBL] [Abstract][Full Text] [Related]
7. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
Xiong W; Wu X; Starnes S; Johnson SK; Haessler J; Wang S; Chen L; Barlogie B; Shaughnessy JD; Zhan F
Blood; 2008 Nov; 112(10):4235-46. PubMed ID: 18337559
[TBL] [Abstract][Full Text] [Related]
8. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
Chang H; Yeung J; Qi C; Xu W
Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
Gaballa S; Saliba RM; Srour S; Lu G; Brammer JE; Shah N; Bashir Q; Patel K; Bock F; Parmar S; Hosing C; Popat U; Delgado R; Rondon G; Shah JJ; Manasanch EE; Orlowski RZ; Champlin R; Qazilbash MH
Am J Hematol; 2016 Oct; 91(10):E442-7. PubMed ID: 27420405
[TBL] [Abstract][Full Text] [Related]
10. Clonal competition with alternating dominance in multiple myeloma.
Keats JJ; Chesi M; Egan JB; Garbitt VM; Palmer SE; Braggio E; Van Wier S; Blackburn PR; Baker AS; Dispenzieri A; Kumar S; Rajkumar SV; Carpten JD; Barrett M; Fonseca R; Stewart AK; Bergsagel PL
Blood; 2012 Aug; 120(5):1067-76. PubMed ID: 22498740
[TBL] [Abstract][Full Text] [Related]
11. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
[TBL] [Abstract][Full Text] [Related]
12. Co-evolution of tumor and immune cells during progression of multiple myeloma.
Liu R; Gao Q; Foltz SM; Fowles JS; Yao L; Wang JT; Cao S; Sun H; Wendl MC; Sethuraman S; Weerasinghe A; Rettig MP; Storrs EP; Yoon CJ; Wyczalkowski MA; McMichael JF; Kohnen DR; King J; Goldsmith SR; O'Neal J; Fulton RS; Fronick CC; Ley TJ; Jayasinghe RG; Fiala MA; Oh ST; DiPersio JF; Vij R; Ding L
Nat Commun; 2021 May; 12(1):2559. PubMed ID: 33963182
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma clonal evolution in homogeneously treated patients.
Corre J; Cleynen A; Robiou du Pont S; Buisson L; Bolli N; Attal M; Munshi N; Avet-Loiseau H
Leukemia; 2018 Dec; 32(12):2636-2647. PubMed ID: 29895955
[TBL] [Abstract][Full Text] [Related]
14. [Chromosomal abnormalities and clonal evolution in multiple myeloma].
Ishida T
Rinsho Ketsueki; 2014 Oct; 55(10):2036-45. PubMed ID: 25297769
[No Abstract] [Full Text] [Related]
15. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Chen MH; Qi CX; Saha MN; Chang H
Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
[TBL] [Abstract][Full Text] [Related]
16. Progression signature underlies clonal evolution and dissemination of multiple myeloma.
Shen YJ; Mishima Y; Shi J; Sklavenitis-Pistofidis R; Redd RA; Moschetta M; Manier S; Roccaro AM; Sacco A; Tai YT; Mercier F; Kawano Y; Su NK; Berrios B; Doench JG; Root DE; Michor F; Scadden DT; Ghobrial IM
Blood; 2021 Apr; 137(17):2360-2372. PubMed ID: 33150374
[TBL] [Abstract][Full Text] [Related]
17. p53 haploinsufficiency and functional abnormalities in multiple myeloma.
Teoh PJ; Chung TH; Sebastian S; Choo SN; Yan J; Ng SB; Fonseca R; Chng WJ
Leukemia; 2014 Oct; 28(10):2066-74. PubMed ID: 24625551
[TBL] [Abstract][Full Text] [Related]
18.
Drozdkova DH; Gursky J; Minarik J; Überall I; Kolar Z; Trtkova KS
Anticancer Res; 2020 Sep; 40(9):4979-4987. PubMed ID: 32878786
[TBL] [Abstract][Full Text] [Related]
19. BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.
Yang Y; Gu C; Luo C; Li F; Wang M
Med Oncol; 2015 Mar; 32(3):81. PubMed ID: 25698537
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]